Table of Contents
<< Previous Issue | Jun 2019 (Vol: 2019, Issue: 6) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Vertex Expands Gene Therapy Footprint with CRISPR Therapeutics and Exonics Deals
-
Merck & Co. Bolsters Oncology Pipeline with US$773 M Acquisition of Tilos Therapeutics
-
Pfizer to Acquire Array BioPharma for Colorectal Cancer Combo
- Section: Research & Development
-
Bayer Latest to Join Protein Degrader Space with Arvinas Collaboration
-
Janssen Collaborates with Genmab For HexaBody-CD38
-
Gilead Joins Growingly Crowded Protein Degradation Field with Nurix Therapeutics Deal